Immuron Ltd has released a press release.
IMM124E May Offer New Modality for Inhibition of SARS-CoV-2
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Immuron SARS-CoV-2 Research Agreement with Monash University
- Immuron Receives AUD $358,280 R&D Tax Concession Refund
- US DoD NMRC Reports Positive Response to Vaccine
- Immuron Travelers Diarrhea Market Update
- Appendix 4E and 2020 Financial Report
Later from Immuron
- Pause in Trading
- Voluntary Suspension
- Preliminary Final Report
- Immuron planned Acquisition of R&D Vaccine Company
- Reinstatement to Official Quotation
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron